Blue Trust Inc. Increases Holdings in Haleon plc (NYSE:HLN)

Blue Trust Inc. boosted its position in Haleon plc (NYSE:HLN) by 62.4% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 40,173 shares of the company’s stock after purchasing an additional 15,439 shares during the period. Blue Trust Inc.’s holdings in Haleon were worth $425,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. AE Wealth Management LLC boosted its stake in shares of Haleon by 6.1% in the 2nd quarter. AE Wealth Management LLC now owns 19,199 shares of the company’s stock valued at $159,000 after purchasing an additional 1,098 shares in the last quarter. Cardinal Capital Management grew its stake in shares of Haleon by 2.5% during the second quarter. Cardinal Capital Management now owns 46,231 shares of the company’s stock valued at $382,000 after buying an additional 1,140 shares during the last quarter. Endowment Wealth Management Inc. increased its holdings in shares of Haleon by 9.9% in the second quarter. Endowment Wealth Management Inc. now owns 12,867 shares of the company’s stock worth $106,000 after buying an additional 1,161 shares during the period. Portside Wealth Group LLC lifted its stake in shares of Haleon by 2.7% in the 2nd quarter. Portside Wealth Group LLC now owns 44,985 shares of the company’s stock valued at $372,000 after acquiring an additional 1,182 shares during the last quarter. Finally, Hexagon Capital Partners LLC boosted its holdings in Haleon by 18.5% during the 3rd quarter. Hexagon Capital Partners LLC now owns 7,933 shares of the company’s stock valued at $84,000 after acquiring an additional 1,238 shares during the period. 6.67% of the stock is currently owned by institutional investors.

Haleon Price Performance

HLN opened at $9.91 on Wednesday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84. The stock has a market capitalization of $45.25 billion, a PE ratio of 33.03, a price-to-earnings-growth ratio of 2.93 and a beta of 0.26. The stock’s 50 day moving average price is $10.23 and its 200-day moving average price is $9.17. Haleon plc has a 52-week low of $7.70 and a 52-week high of $10.80.

Haleon (NYSE:HLN) last issued its quarterly earnings data on Thursday, August 1st. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). Haleon had a net margin of 9.71% and a return on equity of 13.15%. The company had revenue of $3.50 billion for the quarter, compared to analysts’ expectations of $3.55 billion. During the same period in the previous year, the firm posted $0.08 earnings per share. On average, equities research analysts predict that Haleon plc will post 0.47 EPS for the current year.

Haleon Cuts Dividend

The business also recently disclosed a semi-annual dividend, which was paid on Thursday, September 19th. Shareholders of record on Friday, August 16th were issued a $0.0514 dividend. The ex-dividend date of this dividend was Friday, August 16th. This represents a yield of 1.6%. Haleon’s dividend payout ratio (DPR) is presently 33.33%.

Analysts Set New Price Targets

A number of equities analysts have commented on the company. Berenberg Bank initiated coverage on Haleon in a research note on Tuesday, August 6th. They issued a “buy” rating on the stock. UBS Group raised shares of Haleon to a “strong-buy” rating in a research note on Tuesday, October 1st. The Goldman Sachs Group cut shares of Haleon from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 6th. Finally, Morgan Stanley boosted their price objective on shares of Haleon from $9.90 to $10.95 and gave the company an “overweight” rating in a research report on Friday, September 20th. One research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Haleon has a consensus rating of “Buy” and a consensus target price of $10.95.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.